Biotech Values

[mcbio]

Here is my list of candidates:

1. BiTE antibody/immunotherapy: MITI, CLDX
2. Generic/biosimilar/biobetter: PLX, MNTA
3. Ultrafast insulin: HALO, BIOD
4. Small molecule kinase inhibitor: ARRY, PCYC, EXEL
5. Antibody conjugate: IMGN, SGEN
5. Drug delivery/modification of existing drug: NKTR, HALO
6. Established small/mid cap: BMRN, ONXX

Alright jq, it's been well over a year now. Time to update the list. We can safely remove MITI since they got bought out (well done on that one). I imagine ARQL probably makes your updated list. Who else gets added (SNTA?)? Who drops off?